Rizatriptan in the treatment of migraine
- 1 November 1999
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 21 (11) , 1823-1836
- https://doi.org/10.1016/s0149-2918(00)86731-4
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteersBritish Journal of Clinical Pharmacology, 1999
- Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 1998
- Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo‐Controlled, Outpatient StudyHeadache: The Journal of Head and Face Pain, 1998
- Serotonin 5-HT1B/1D Receptor Agonists in MigraineCNS Drugs, 1998
- Rizatriptan has central antinociceptive effects against durally evoked responsesEuropean Journal of Pharmacology, 1997
- The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasationEuropean Journal of Pharmacology, 1997
- Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonistBritish Journal of Clinical Pharmacology, 1997
- Migraine Symptoms: Results of a Survey of Self‐Reported MigraineursHeadache: The Journal of Head and Face Pain, 1995
- Safety and Efficiency of Ergotamine Tartrate and Dihydroergotamine in the Treatment of Migraine and Status Migrainosus [RETIRED]Neurology, 1995
- Ergotamine Dependency‐ a ReviewHeadache: The Journal of Head and Face Pain, 1987